Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Mar 28, 2016 at 10:50 AM EDT

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.

Chris Lange | Mar 28, 2016 at 10:05 AM EDT

Tactile Systems Prepares for IPO

Tactile Systems Technology has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering…

Chris Lange | Mar 27, 2016 at 10:25 AM EDT

5 Key Biopharma Movers From Last Week

Over the past week, Akorn, Celator Pharmaceuticals and a few other biotech companies made impressive runs.

Chris Lange | Mar 27, 2016 at 10:05 AM EDT

Top 4 Medtech Picks From Merrill Lynch

Merrill Lynch has some ideas about how to take advantage of the trends in health care going forward.

Chris Lange | Mar 24, 2016 at 11:10 AM EDT

Celator Pharma Prices Secondary Offering

Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.

Chris Lange | Mar 24, 2016 at 10:45 AM EDT

Vitae Pharma Prepares for Secondary Offering

Vitae Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering valued at up to…

Chris Lange | Mar 24, 2016 at 8:50 AM EDT

Portola Pharma Top-Line Results Miss Par for the Course

Portola Pharmaceuticals made waves early on Thursday morning with less than favorable top-line results.

Chris Lange | Mar 23, 2016 at 11:15 AM EDT

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.

Chris Lange | Mar 23, 2016 at 9:05 AM EDT

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.

Chris Lange | Mar 22, 2016 at 11:05 AM EDT

Akorn Back on Track to Restate Results

Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full…

Chris Lange | Mar 22, 2016 at 8:45 AM EDT

Moleculin Gears Up for IPO

Moleculin Biotech plans to list up to 2 million shares at an estimated $5.50 apiece in an IPO valued at…

Chris Lange | Mar 21, 2016 at 12:15 PM EDT

Why Investors Still Like Celator Pharma Despite a Loss

Celator Pharmaceuticals reported its fourth-quarter financial results before the markets opened on Monday.

Chris Lange | Mar 21, 2016 at 11:40 AM EDT

Advaxis Soars on Positive Survival Results

Advaxis made waves in the markets on Monday following the release of positive data from its most recent study.

Jon C. Ogg | Mar 21, 2016 at 9:50 AM EDT

Why GW Pharma Could More Than Double From Cannabinoid Drugs

What are investors supposed to make of a Bank of America Merrill Lynch call that shows GW Pharmaceuticals worth over…

Chris Lange | Mar 21, 2016 at 9:05 AM EDT

BioMarin Sinks Despite Meeting Primary Endpoint

BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.

1 … 217 218 219 220 221 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Tactile Systems Prepares for IPO

5 Key Biopharma Movers From Last Week

Top 4 Medtech Picks From Merrill Lynch

Celator Pharma Prices Secondary Offering

Vitae Pharma Prepares for Secondary Offering

Portola Pharma Top-Line Results Miss Par for the Course

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

How Ionis Pharma Beat a Biotech Giant

Akorn Back on Track to Restate Results

Moleculin Gears Up for IPO

Why Investors Still Like Celator Pharma Despite a Loss

Advaxis Soars on Positive Survival Results

Why GW Pharma Could More Than Double From Cannabinoid Drugs

BioMarin Sinks Despite Meeting Primary Endpoint

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: AMD Reports Q1 Earnings Tonight. Will the Stock Continue Its 255% 1-Year Explosion?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

Health and Healthcare Articles

All Health and Healthcare Articles

Alder Biopharma Soars on Positive Mid-Stage Trial Results

Tactile Systems Prepares for IPO

5 Key Biopharma Movers From Last Week

Top 4 Medtech Picks From Merrill Lynch

Celator Pharma Prices Secondary Offering

Vitae Pharma Prepares for Secondary Offering

Portola Pharma Top-Line Results Miss Par for the Course

Jefferies Identifies 5 Top Biotech Stocks for Huge Upside

How Ionis Pharma Beat a Biotech Giant

Akorn Back on Track to Restate Results

Moleculin Gears Up for IPO

Why Investors Still Like Celator Pharma Despite a Loss

Advaxis Soars on Positive Survival Results

Why GW Pharma Could More Than Double From Cannabinoid Drugs

BioMarin Sinks Despite Meeting Primary Endpoint

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: AMD Reports Q1 Earnings Tonight. Will the Stock Continue Its 255% 1-Year Explosion?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

Featured Reads

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income